Case report: Immune modulation after PD-1 inhibitor therapy in a patient with extranodal NK/T-cell lymphoma secondary to chronic active Epstein-Barr virus disease unveiled by single-cell transcriptomics
Open Access
- 17 April 2023
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14
Abstract
Chronic active Epstein-Barr virus disease (CAEBV) is a systemic lymphoproliferative disorder that is closely linked to Epstein-Barr virus (EBV) infection. The clinical course and severity of CAEBV can vary, and in some cases, it can progress to overt lymphoma, which is characterized by extranodal natural killer/T-cell lymphoma (ENKTL) and has a poor clinical outcome. Although anti-programmed cell death protein-1 (PD-1) therapy has shown effectiveness in some patients with EBV-associated disease, it has been less successful in others, and the exact mechanism of action of PD-1 inhibitor therapy in these diseases remains unclear. In this report, we describe a patient who was diagnosed with ENKTL secondary to CAEBV and experienced rapid disease progression accompanied by hyperinflammation after receiving PD-1 inhibitor therapy. Single-cell RNA sequencing revealed a significant increase in the patient’s lymphocyte count, especially in natural killer cells, with increased activity following PD-1 inhibitor therapy. This case raises questions about the efficacy and safety of PD-1 inhibitor therapy in patients with EBV-associated diseases.Keywords
This publication has 25 references indexed in Scilit:
- Investigational PD-1 inhibitors in HL and NHL and biomarkers for predictors of response and outcomeExpert Opinion on Investigational Drugs, 2017
- PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginaseBlood, 2017
- Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependentScience, 2017
- Molecular and Biochemical Aspects of the PD-1 Checkpoint PathwayNew England Journal of Medicine, 2016
- The CXCL8-CXCR1/2 pathways in cancerCytokine & Growth Factor Reviews, 2016
- Advances in the pathogenesis of primary and secondary haemophagocytic lymphohistiocytosis: differences and similaritiesBritish Journal of Haematology, 2016
- Phenotypic Diversity and Plasticity in Circulating Neutrophil Subpopulations in CancerCell Reports, 2015
- Epstein–Barr virus-positive T/NK-cell lymphoproliferative disordersExperimental & Molecular Medicine, 2015
- EBV-associated T/NK–cell lymphoproliferative diseases in nonimmunocompromised hosts: prospective analysis of 108 casesBlood, 2012
- Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United StatesBlood, 2011